None of the people who developed clots after vaccination had been recently given heparin. This condition “is diagnosable and treatable.” “This vector may, in certain individuals, generate antibodies that interfere with platelet function and produce a condition similar to heparin-induced thrombocytopenia,” Adalja said. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security and an infectious disease expert, the similarity of the rare clots reported after both the Johnson & Johnson and AstraZeneca shots may suggest that these adenovirus vectors may be linked to risk of developing blood clots. In this type of vaccine, a modified version of a virus (also called a vector) is used to deliver instructions to the immune system to help prevent infections.Īccording to Dr. Robert Bona, a Yale Medicine hematologist and professor of medicine at Yale School of Medicine.īoth the AstraZeneca and Johnson & Johnson COVID-19 vaccines are adenovirus vaccines. They’re developing low platelet counts and have formed high levels of antibodies against platelets, explains Dr. In these instances, the people experienced clots in unusual locations, like veins in the brain and abdomen. Two recent studies published in The New England Journal of Medicine explored the possibility that a small number of people vaccinated with the AstraZeneca shot who experienced clots may have developed cerebral venous sinus thrombosis (CVST) in combination with low levels of blood platelets, called thrombotic thrombocytopenia.ĬVST is known to occur in a small percentage of people who receive heparin, a type of blood thinner. It’s unclear what exactly is causing the clots, but recent research suggests the shots may trigger an immune response that facilitates blood clotting. Studies suggest the shots could be triggering an immune response that causes clotting, but more research is needed to better understand the potential link.
Many health experts say temporarily halting the use of the Johnson & Johnson shot - a vaccine that’s highly effective at preventing hospitalization and death from COVID-19 - could slow the vaccine rollout and fuel vaccine hesitancy. The clots appear to be similar to the unusual, rare clots reported in a handful of people who received the AstraZeneca COVID-19 vaccine. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended halting the use of the vaccine to alert healthcare professionals about the clots and ensure they’re prepared to diagnose and treat them. Of the six women who experienced clots, one died and another is hospitalized.Įxperts are still investigating whether the vaccine was the cause of these events. Federal drug safety regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine after six women experienced blood clots after vaccination.
0 kommentar(er)
